Daiichi Pharmaceutical Co., Ltd.

Daiichi Sankyo Company, Limited

Yumi Nakamoto

Makoto Ono

Hiroyuki Naito

Hideyuki Kanno

Kenji Yoshikawa

Satoshi Komoriya

Noriyasu Haginoya

Tsutomu Nagata

Kouichi Uoto

Masatoshi Nagamochi

Toshiharu Yoshino

Syozo Kobayashi

Akiyoshi Mochizuki

Toshiharu Ohta

Masashi Hasegawa

Hiroshi Susaki

Yuichi Ochiai

Ryoko Kitazawa

Tatsuya Nishi

A compound of the general formula (I): [wherein, Rrepresents a halogen atom, or the like, Rrepresents a hydrogen atom, or the like, Rand R, each independently, represent a hydrogen atom, a Calkyl group, or the like, Rrepresents a hydrogen atom, a halogen atom, or the like, Rrepresents a hydrogen atom, a halogen atom, or the like, Rand R, each independently, represent a hydrogen atom, a halogen atom, or the like, Rand R, each independently, represent a hydrogen atom, a Calkyl group, Rand R, each independently, represent a hydrogen atom, a Calkyl group, or the like, X represents an oxygen atom, a group &#x2014;CH&#x2014;, or the like, Y represents a nitrogen atom, a group &#x2550;CH&#x2014;, or the like, and Z represents a nitrogen atom, or the like] or a pharmacologically acceptable salt thereof, which has an excellent suppressive action on platelet aggregation, and is useful for prevention and/or treatment of thromboembolism.

3-(biaryloxy)propionic acid derivatives for prevention and/or treatment of thromboembolic diseases

A compound represented by formula (1):Q-Q-T-N(R)-Q-N(R)-T-Q&#x2003;&#x2003;(1)[wherein Rand Rare hydrogen atoms or the like; Qis a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Qis a single bond or the like; Qrepresents the following group: (wherein Qis an alkylene group having 1 to 8 carbon atoms, or the like); and Tand Tare carbonyl groups or the like], a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

Diamine derivatives

A compound represented by the general formula (1):Q-Q-T-N(R)-Q-N(R)-T-Q&#x2003;&#x2003;(1)wherein Rand Rare hydrogen atoms or the like; Qis a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Qis a single bond or the like; Qis a group in which Qis an alkylene group having 1 to 8 carbon atoms, or the like; and Tand Tare carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

Growing community of inventors

Tokyo, Japan

Yumi Nakamoto